These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 26080005)

  • 1. Biological effects of interleukin-6: Clinical applications in autoimmune diseases and cancers.
    Ho LJ; Luo SF; Lai JH
    Biochem Pharmacol; 2015 Sep; 97(1):16-26. PubMed ID: 26080005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.
    Tanaka T; Narazaki M; Ogata A; Kishimoto T
    Semin Immunol; 2014 Feb; 26(1):88-96. PubMed ID: 24594001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
    Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
    Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapeutic implication of IL-6 blockade.
    Tanaka T; Kishimoto T
    Immunotherapy; 2012 Jan; 4(1):87-105. PubMed ID: 22150003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases.
    Tanaka T; Narazaki M; Kishimoto T
    FEBS Lett; 2011 Dec; 585(23):3699-709. PubMed ID: 21419125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-6 blockade in ocular inflammatory diseases.
    Mesquida M; Leszczynska A; Llorenç V; Adán A
    Clin Exp Immunol; 2014 Jun; 176(3):301-9. PubMed ID: 24528300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-6: A Masterplayer in the Cytokine Network.
    Uciechowski P; Dempke WCM
    Oncology; 2020; 98(3):131-137. PubMed ID: 31958792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic targeting of the interleukin-6 receptor.
    Tanaka T; Narazaki M; Kishimoto T
    Annu Rev Pharmacol Toxicol; 2012; 52():199-219. PubMed ID: 21910626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by anti-interluekin-6 receptor antibody.
    Mihara M; Ohsugi Y; Kishimoto T
    Biofactors; 2009; 35(1):47-51. PubMed ID: 19319845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic uses of anti-interleukin-6 receptor antibody.
    Kang S; Tanaka T; Kishimoto T
    Int Immunol; 2015 Jan; 27(1):21-9. PubMed ID: 25142313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-interleukin-6 receptor antibody therapy in rheumatic diseases.
    Nakahara H; Nishimoto N
    Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):373-81. PubMed ID: 17214583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-6: designing specific therapeutics for a complex cytokine.
    Garbers C; Heink S; Korn T; Rose-John S
    Nat Rev Drug Discov; 2018 Jun; 17(6):395-412. PubMed ID: 29725131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-6 as a key player in systemic inflammation and joint destruction.
    Fonseca JE; Santos MJ; Canhão H; Choy E
    Autoimmun Rev; 2009 Jun; 8(7):538-42. PubMed ID: 19189867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases.
    Tanaka T; Kishimoto T
    Int J Biol Sci; 2012; 8(9):1227-36. PubMed ID: 23136551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humanized antihuman IL-6 receptor antibody, tocilizumab.
    Nishimoto N; Kishimoto T
    Handb Exp Pharmacol; 2008; (181):151-60. PubMed ID: 18071945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The biology and medical implications of interleukin-6.
    Tanaka T; Kishimoto T
    Cancer Immunol Res; 2014 Apr; 2(4):288-94. PubMed ID: 24764575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection: Therapeutic Implications of IL-6 Receptor Blockade.
    Jordan SC; Choi J; Kim I; Wu G; Toyoda M; Shin B; Vo A
    Transplantation; 2017 Jan; 101(1):32-44. PubMed ID: 27547870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities.
    Kampan NC; Xiang SD; McNally OM; Stephens AN; Quinn MA; Plebanski M
    Curr Med Chem; 2018; 25(36):4785-4806. PubMed ID: 28707587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders.
    Paul-Pletzer K
    Drugs Today (Barc); 2006 Sep; 42(9):559-76. PubMed ID: 17028666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential Application of Biological Products for the Treatment of Ocular Surface Inflammation.
    Sakimoto T
    Cornea; 2015 Nov; 34 Suppl 11():S153-7. PubMed ID: 26448173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.